References
1. Wesevich A, Goldstein DA, Paydary K, Peer CJ, Figg WD, Ratain MJ. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. British journal of cancer 2023.
2. Achini-Gutzwiller FR, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Lankester AC, Bredius RGM, van Tol MJD, Moes D, Schilham MW. Development and Validation of an Efficient and Highly Sensitive Enzyme-Linked Immunosorbent Assay for Alemtuzumab Quantification in Human Serum and Plasma. Ther Drug Monit 2023; 45: 79-86.
3. Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, de Vries A. Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients. Ther Drug Monit 2017; 39: 316-21.
4. Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellstrom B, Holdaas H, Asberg A, Bergan S, Vethe NT, Warren DJ. A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. Ther Drug Monit 2019; 41: 11-18.
5. Suh K, Kyei I, Hage DS. Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review. J Sep Sci 2022; 45: 2077-92.
6. Todoroki K, Mizuno H, Sugiyama E, Toyo’oka T. Bioanalytical methods for therapeutic monoclonal antibodies and antibody-drug conjugates: A review of recent advances and future perspectives. J Pharm Biomed Anal 2020; 179: 112991.
7. Chhun S, Trauchessec M, Melicine S, Nicolas F, Miele A, Lukic S, Vilain E, Amrouche L, Lebert D, Anglicheau D, Tartour E, Zuber J. A Validated LC-MS/MS Method for Performing Belatacept Drug Monitoring in Renal Transplantation. Biomedicines 2023; 11: 2955.
8. Mochizuki T, Shibata K, Naito T, Shimoyama K, Ogawa N, Maekawa M, Kawakami J. LC-MS/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification. J Pharm Anal 2022; 12: 852-59.
9. Truffot A, Jourdil JF, Seitz-Polski B, Malvezzi P, Brglez V, Stanke-Labesque F, Gautier-Veyret E. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. Clin Biochem 2021; 87: 60-66.
10. Willeman T, Jourdil JF, Gautier-Veyret E, Bonaz B, Stanke-Labesque F. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn’s disease. Analytica chimica acta 2019; 1067: 63-70.
11. Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. The AAPS journal 2012; 14: 559-70.
12. Zou P. Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point. The AAPS journal 2023; 25: 31.
13. Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein & cell 2018; 9: 15-32.
14. Baldwin WM, 3rd, Valujskikh A, Fairchild RL. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals. Am J Transplant 2019; 19: 1881-87.
15. Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol 2019; 10: 2040620719874728.
16. Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Frontiers in immunology 2020; 11: 1951.
17. Vaisman-Mentesh A, Rosenstein S, Yavzori M, Dror Y, Fudim E, Ungar B, Kopylov U, Picard O, Kigel A, Ben-Horin S, Benhar I, Wine Y. Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists. Frontiers in immunology 2019; 10: 2921.
18. Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y, Wittrup KD. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. mAbs 2016; 8: 1269-75.
19. Liu S, Shah DK. Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies. The AAPS journal 2023; 25: 48.
20. Kantasiripitak W, Outtier A, Wicha SG, Kensert A, Wang Z, Sabino J, Vermeire S, Thomas D, Ferrante M, Dreesen E. Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT: pharmacometrics & systems pharmacology 2022; 11: 1045-59.
21. Kantasiripitak W, Wicha SG, Thomas D, Hoffman I, Ferrante M, Vermeire S, van Hoeve K, Dreesen E. A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases. Journal of Crohn’s & colitis 2023; 17: 896-908.
22. Strik AS, Löwenberg M, Mould DR, Berends SE, Ponsioen CI, van den Brande JMH, Jansen JM, Hoekman DR, Brandse JF, Duijvestein M, Gecse KB, de Vries A, Mathôt RA, D’Haens GR. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol 2021; 56: 145-54.
23. Ternant D, Passot C, Aubourg A, Goupille P, Desvignes C, Picon L, Lecomte T, Mulleman D, Paintaud G. Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. Clin Pharmacokinet 2017.
24. Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278-91.
25. Pressly MA, Peletier LA, Zheng S, Sharma VD, Lien YTK, Wang W, Zhou H, Schmidt S. The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies. CPT: pharmacometrics & systems pharmacology 2023; 12: 639-55.
26. Jodele S, Mizuno K, Sabulski A, Vinks AA. Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies. Clin Pharmacol Ther 2023; 114: 511-14.
27. Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv 2022; 6: 1454-63.
28. de Graav GN, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink DA. Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation. Therapeutic Drug Monitoring 2015; 37: 560-7.
29. Meesters-Ensing JI, Admiraal R, Ebskamp L, Lacna A, Boelens JJ, Lindemans CA, Nierkens S. Therapeutic Drug Monitoring of Anti-Thymocyte Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept. Frontiers in pharmacology 2022; 13: 828094.
30. van Vugt LK, Schagen MR, de Weerd A, Reinders ME, de Winter BC, Hesselink DA. Investigational drugs for the treatment of kidney transplant rejection. Expert Opin Investig Drugs 2022; 31: 1087-100.
31. Lorant T, Bengtsson M, Eich T, Eriksson BM, Winstedt L, Jarnum S, Stenberg Y, Robertson AK, Mosen K, Bjorck L, Backman L, Larsson E, Wood K, Tufveson G, Kjellman C. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant 2018.
32. Bertrand D, Brunel M, Lebourg L, Scemla A, Lemoine M, Amrouche L, Laurent C, Legendre C, Guerrot D, Anglicheau D, Sberro-Soussan R. Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France. Transpl Int 2023; 36: 11328.
33. Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. Ther Drug Monit 2017; 39: 364-69.
34. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-28.
35. Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, Ducloux D, Chatelet V, Moulin B, Freguin C, Hazzan M, Lang P, Legendre C, Merville P, Mourad G, Mousson C, Pouteil-Noble C, Purgus R, Rerolle JP, Sayegh J, Westeel PF, Zaoui P, Boivin H, Le Gouge A, Lebranchu Y. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation 2016; 100: 391-9.
36. Mazilu D, Opriş D, Gainaru C, Iliuta M, Apetrei N, Luca G, Borangiu A, Gudu T, Peltea A, Groseanu L, Constantinescu C, Saulescu I, Bojinca V, Balanescu A, Predeteanu D, Ionescu R. Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Res Int 2014; 2014: 702701.
37. Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 2012; 97: 1431-8.
38. Rozman S, Grabnar I, Novaković S, Mrhar A, Jezeršek Novaković B. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol 2017; 83: 1782-90.
39. Techa-Angkoon P, Siritho S, Tisavipat N, Suansanae T. Current evidence of rituximab in the treatment of multiple sclerosis. Mult Scler Relat Disord 2023; 75: 104729.
40. Zwart TC, Bezstarosti S, Achini FR, Reinders MEJ, Schilham MW, Heidt S, Guchelaar HJ, de Fijter JW, Moes D. Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation. Br J Clin Pharmacol 2022.
41. Hullegie-Peelen DM, van der Zwan M, Clahsen-van Groningen MC, Mustafa DAM, Baart SJ, Reinders MEJ, Baan CC, Hesselink DA. Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection. Clinical Pharmacology & Therapeutics 2022; n/a.
42. Hesselink DA, Hullegie-Peelen DM, van Vugt LK. Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients. Pharmacogenomics 2022; 23: 567-70.
43. Scalzo RE, Sanoff SL, Rege AS, Kwun J, Knechtle SJ, Barisoni L, Byrns JS. Daratumumab Use Prior to Kidney Transplant and T Cell-Mediated Rejection: A Case Report. American journal of kidney diseases : the official journal of the National Kidney Foundation 2023; 81: 616-20.
44. Cabezas L, Jouve T, Malvezzi P, Janbon B, Giovannini D, Rostaing L, Noble J. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review. Frontiers in immunology 2022; 13: 839380.
45. January SE, Fester KA, Halverson LP, Witt CA, Byers DE, Vazquez-Guillamet R, Alexander-Brett J, Tague LK, Kreisel D, Gelman A, Puri V, Bahena RN, Takahashi T, Hachem RR, Kulkarni HS. Tocilizumab for antibody-mediated rejection treatment in lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2023; 42: 1353-57.
46. Miller CL, Madsen JC. IL-6 Directed Therapy in Transplantation. Current transplantation reports 2021; 8: 191-204.
47. Weinhard J, Noble J, Jouve T, Malvezzi P, Rostaing L. Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review. J Clin Med 2021; 10.
48. Arrivé C, Jacquet M, Gautier-Veyret E, Jouve T, Noble J, Lombardo D, Rostaing L, Stanke-Labesque F. Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab-A Preliminary Study. J Clin Med 2023; 12.
49. Massat M, Congy-Jolivet N, Hebral AL, Esposito L, Marion O, Delas A, Colombat M, Faguer S, Kamar N, Del Bello A. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant 2021; 21: 1641-49.
50. Tang ZC, Hui H, Shi C, Chen X. New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses. Renal failure 2023; 45: 2231264.
51. Coutance G, Kobashigawa JA, Kransdorf E, Loupy A, Desiré E, Kittleson M, Patel JK. Intermediate-term outcomes of complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2023; 42: 1464-68.
52. Kleiboeker HL, Prom A, Paplaczyk K, Myers CN. A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience. Ann Pharmacother 2023: 10600280231213112.